Synthetic lethality offers a new approach to kill tumor cells, explains Moffitt researcher

The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs. Alan F. List, MD, president and CEO of Moffitt Cancer Center, co-authored an article on synthetic lethality featured in the Oct. 30 issue of the New England Journal of Medicine. —> Read More Here

1 2 3 325